Related Experiment Videos
p53 Mutation and MDM2 amplification in human soft tissue sarcomas
F S Leach1, T Tokino, P Meltzer
1Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231.
Cancer Research
|May 15, 1993
Summary
Genetic alterations in the p53 and MDM2 genes were found in half of soft tissue sarcomas. These changes in p53 or MDM2 appear to be alternative pathways for tumor growth suppression.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The p53 tumor suppressor gene and its regulator, MDM2, play critical roles in cell cycle control and apoptosis.
- Dysregulation of the p53-MDM2 pathway is implicated in various human cancers, including soft tissue sarcomas.
Purpose of the Study:
- To investigate the frequency and nature of alterations in the p53 and MDM2 genes in human soft tissue sarcomas.
- To explore the relationship between p53 and MDM2 genetic alterations and their functional consequences in tumor suppression.
Main Methods:
- Analysis of p53 gene alterations (point mutations, deletions, overexpression) in 24 soft tissue sarcoma samples.
- Detection of MDM2 gene amplification using molecular techniques.
- Immunohistochemical analysis using monoclonal antibodies to detect MDM2 protein localization and overexpression.
Main Results:
- Alterations in the p53 gene were observed in one-third (8 of 24) of the sarcomas.
- MDM2 gene amplification was detected in another 8 tumors; no tumor exhibited alterations in both genes.
- Immunohistochemistry confirmed nuclear localization and overexpression of MDM2 in tumors with MDM2 gene amplification.
Conclusions:
- Genetic alterations in p53 and MDM2 occur in approximately half of the studied soft tissue sarcomas.
- These findings support the hypothesis that p53 and MDM2 genetic alterations represent alternative mechanisms for inactivating the cell growth regulatory pathway.